Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-06-07 Declaration of Voting R…
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
2022 年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the company's second extraordinary general meeting in 2022. It details the meeting date, attendance, agenda items, voting results, and legal opinions on the meeting's validity. The content focuses on the official voting results and decisions made at the shareholders' meeting, including board member appointments and amendments to company bylaws. There are no financial statements or detailed financial performance data present. The document is a formal announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it contains detailed voting results rather than just a notice of a report publication, so it is not an RPA. Therefore, the classification is DVA with high confidence.
2022-06-07 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2022年第二次临时股东大会法律意见书
Regulatory Filings
2022-06-07 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2020年第一期股权激励计划相关事项的法律意见书
Regulatory Filings
2022-05-31 Chinese
监事会关于公司2020年第一期股权激励计划解限售条件成就及部分限制性股票回购注销相关事项的审核意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Inner Mongolia Datang Pharmaceutical Co., Ltd. regarding the review and opinions on matters related to the company's 2020 first equity incentive plan, specifically about the lifting of lock-up conditions and the repurchase and cancellation of some restricted stocks. It references regulatory rules from the Beijing Stock Exchange and company bylaws, and discusses compliance and procedural legality. The document is an official announcement of supervisory board opinions and decisions related to equity incentive plans and stock repurchase, not a full financial report or detailed management discussion. It is also not a proxy solicitation or voting result announcement, but rather a regulatory announcement about corporate governance and stock incentive plan matters. Given the content and length (1231 characters), it fits best under Regulatory Filings (RNS) as it does not contain full financial statements or detailed financial analysis, nor is it a simple report publication announcement. Therefore, the classification is RNS with high confidence.
2022-05-31 Chinese
关于调整公司2020 年第一期股权激励计划限制性股票授予数量的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of the company's 2020 first equity incentive plan's restricted stock grant quantity. It details board meeting approvals, regulatory compliance, and the calculation method for adjusting the stock quantity due to equity distribution. The document is a formal announcement of changes related to a stock incentive plan, not a full financial report or audit. It does not contain financial statements or earnings data, nor is it a call transcript or AGM material. It is not a report publication announcement since it contains substantive content about the adjustment. The document fits best under Capital/Financing Update (CAP) as it relates to changes in equity incentive plans and stock grants, which affect the company's capital structure.
2022-05-31 Chinese
关于完成工商变更登记及章程备案的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of industrial and commercial registration changes and the filing of amended articles of association for Inner Mongolia Datang Pharmaceutical Co., Ltd. It details the change in registered capital and confirms the completion of related administrative procedures. The document is short (1015 characters) and serves as a formal notification of corporate changes rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the change. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about corporate registration changes.
2022-05-31 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.